German medicinal cannabis distributor Fette Pharma GmbH has reported the successful completion of a strategic restructuring, almost seven months after an investor consortium led by entrepreneur Jörg Löser acquired the Egelsbach-based company in September 2025.
The deal marked the end of Fette Pharma’s previous ownership under Salis Holding GmbH, a Frankfurt-based holding company that had controlled the business since 2019.
The incoming consortium, which also includes Maik Dobiey, who now serves as co-Managing Director alongside Löser, has since completed what the company describes as a significant overhaul of its supply chain, quality assurance processes, and distribution infrastructure.
“Our goal from the outset was not only to stabilise Fette Pharma, but also to position it as an innovation leader in the field of cannabinoid therapy,” said Löser. “Today we can say: Fette Pharma is back, with more effective structures, stronger partners, but with the same high level of pharmaceutical expertise and a clear focus on patient care.”
Fette Pharma is one of the longer-standing players in the sector, bringing roughly five decades of pharmaceutical heritage to a market that has only relatively recently opened up to cannabis-based medicines. Since 2017, when Germany first permitted medicinal cannabis prescriptions, the company has been a key supplier of pharmaceutical cannabis products to pharmacies and medical facilities
In late 2022, it launched RE:CANNIS, an exclusive partnership with Israeli cultivator Cannbit Pharmaceuticals, marking one of the first introductions of Israeli-grown medicinal cannabis to the German market.
The collaboration was built on Cannbit’s research legacy, including ties to work from the late cannabis research pioneer Professor Raphael Mechoulam, and gave Fette Pharma access to therapy data drawn from over 40,000 patients across more than 37 clinical and pre-clinical studies.
Products under the RE:CANNIS brand are EU-GMP and GDP certified, covering both flower and extract formats across a range of indications, including chronic pain, fibromyalgia, neurological conditions, and inflammatory bowel disease.
Its restructuring has preserved this pharmaceutical core, while bringing cannabis industry expertise to the forefront under Löser and Dobiey.
Looking ahead, Fette Pharma says it plans to expand its product portfolio and build new international partnerships during the current fiscal year, while expanding its foundations in the thriving German medical market.
The company has also repositioned itself more explicitly as a market entry partner for international cultivators and brands seeking access to German pharmacies, offering GDP- and GMP-certified logistics, integrated supply chain support, and direct pharmacy network access without broker intermediaries.
The post German Distributor Fette Pharma Emerges From Restructuring Under New Investor Leadership appeared first on Business of Cannabis.
Continue reading...
The deal marked the end of Fette Pharma’s previous ownership under Salis Holding GmbH, a Frankfurt-based holding company that had controlled the business since 2019.
The incoming consortium, which also includes Maik Dobiey, who now serves as co-Managing Director alongside Löser, has since completed what the company describes as a significant overhaul of its supply chain, quality assurance processes, and distribution infrastructure.
“Our goal from the outset was not only to stabilise Fette Pharma, but also to position it as an innovation leader in the field of cannabinoid therapy,” said Löser. “Today we can say: Fette Pharma is back, with more effective structures, stronger partners, but with the same high level of pharmaceutical expertise and a clear focus on patient care.”
READ MORE…
Berlin 2026: European Cannabis M&A Finds its Footing
Germany’s Cannabis Reform Shows No Signs of Harm its Critics Predicted, Government Mandated Data Shows
Stable Consumption, Falling Arrests: Germany’s Cannabis Landscape 2-Years On
Fette Pharma is one of the longer-standing players in the sector, bringing roughly five decades of pharmaceutical heritage to a market that has only relatively recently opened up to cannabis-based medicines. Since 2017, when Germany first permitted medicinal cannabis prescriptions, the company has been a key supplier of pharmaceutical cannabis products to pharmacies and medical facilities
In late 2022, it launched RE:CANNIS, an exclusive partnership with Israeli cultivator Cannbit Pharmaceuticals, marking one of the first introductions of Israeli-grown medicinal cannabis to the German market.
The collaboration was built on Cannbit’s research legacy, including ties to work from the late cannabis research pioneer Professor Raphael Mechoulam, and gave Fette Pharma access to therapy data drawn from over 40,000 patients across more than 37 clinical and pre-clinical studies.
Products under the RE:CANNIS brand are EU-GMP and GDP certified, covering both flower and extract formats across a range of indications, including chronic pain, fibromyalgia, neurological conditions, and inflammatory bowel disease.
Its restructuring has preserved this pharmaceutical core, while bringing cannabis industry expertise to the forefront under Löser and Dobiey.
Looking ahead, Fette Pharma says it plans to expand its product portfolio and build new international partnerships during the current fiscal year, while expanding its foundations in the thriving German medical market.
The company has also repositioned itself more explicitly as a market entry partner for international cultivators and brands seeking access to German pharmacies, offering GDP- and GMP-certified logistics, integrated supply chain support, and direct pharmacy network access without broker intermediaries.
The post German Distributor Fette Pharma Emerges From Restructuring Under New Investor Leadership appeared first on Business of Cannabis.
Continue reading...
hopfully they come to the UK market
